

Press Release October 19, 2017



AlzeCure to present data from its two main projects at the 10th annual Conference on Clinical Trials for Alzheimer’s Disease (CTAD)

**Stockholm, Sweden, October 19, 2017 - AlzeCure Pharma (AlzeCure) today announced that data from its two main projects – NeuroRestore and Alzstatin – will be presented at the 10th annual Conference on Clinical Trials for Alzheimer’s Disease (CTAD) in Boston, MA, USA on November 1 - 4, 2017.**

All presentations are submitted to a scientific committee and those approved will be able to present their findings, which has to be original data or reinterpretation of data in light of new clinical results.

The NeuroRestore project, currently in preclinical development, will be presented by Dr. Pontus Forsell. Focus will be on the repurposing of ACD855 - a novel therapy for AD affecting key neurotrophin signaling pathways. The presentation will include new in vitro and in vivo data supporting its claim as a cognitive enhancer, as well as future plans around preclinical development and clinical studies.

**Key messages about NeuroRestore:**

*Novel mechanism*

- ACD855 targets key neuronal mechanisms which are essential for memory and other cognitive functions
- It enhances neurotrophin signaling and promotes neuronal activity
- One of the targeted neurotrophins, BDNF, was recently shown to have strong genetic linkage to AD

*Safe and effective Drug*

- ACD855 is developed as a cognitive enhancer, i.e. symptomatic treatment of AD, but also has strong potential for disease modifying properties
- Has good pharmacokinetic properties
- Known drug with favorable safety profile

“It is also a unique business opportunity. We have an existing veterinary medicine with proven safety profile and a strong backup program available. It can also act as additive to existing drugs, enhancing market penetration”, commented Johan Sandin, CEO of AlzeCure.

The Alzstatin project, currently in preclinical development, will be presented by Professor Bengt Winblad. The presentation will focus on the novel asset ACD678; the potential of gamma-secretase modulators in the field of Alzheimer’s disease, supporting in vitro and in vivo data; and the plans for its future development.

## **Key messages about Alzstatin:**

### *Strong mechanism*

- A gamma-secretase modulator (GSM)
- Targets the key pathogen in Alzheimer - A $\beta$ 42
- Effective in vivo

### *Strong asset*

- Good pharmacokinetic properties
- Enters brain efficiently, a weak point of the current antibody therapies
- Emanates from big pharma
- Early tox studies support further development

“The AlzeCure team is supported by some of the most renowned experts in the AD field, including Professor Bengt Winblad and Professor Henrik Zetterberg. We have high hopes to advance these highly interesting projects into the next development phase”, said Johan Sandin.

Abstracts accepted for presentation at CTAD 2017 will be published in a special issue of the Journal for Prevention of Alzheimer's Disease after the event.

(<http://www.jpreventionalzheimer.com>).

### **For more information, please contact:**

Johan Sandin, PhD

CEO, AlzeCure Pharma

Mobile: +46 70-373 88 24

Email: [johan.sandin@alzecurepharma.com](mailto:johan.sandin@alzecurepharma.com)

### **About AlzeCure Pharma:**

AlzeCure Pharma is a Swedish pharmaceutical company focused on the development of novel treatments for Alzheimer's disease. This severe and fatal disease, which today affects more than 30 million people worldwide, is currently lacking in effective treatment. The company's overall goal is to help benefit patients and relatives as well as society.

The team behind AlzeCure Pharma has extensive experience from small and large pharmaceutical companies, and in addition, it has a close network of Key Opinion Leaders in the field, including Bengt Winblad, one of the most prominent researchers and opinion makers in Alzheimer's research.

In June 2017, AlzeCure Pharma AB got 70 MSEK in private equity for the continued development of their project portfolio towards clinical studies, which is planned to be initiated during 2018. Moreover, the company is planning an IPO on Nasdaq First North during the second half of next year.